Pediapharm Inc. Announces Changes to Board of Directors; Appoints Michael P. Mueller
02 Juni 2014 - 1:30PM
Marketwired
Pediapharm Inc. Announces Changes to Board of Directors; Appoints
Michael P. Mueller
MONTREAL, QUEBEC--(Marketwired - Jun 2, 2014) - Pediapharm Inc.
("Pediapharm" or the "Corporation") (TSX-VENTURE:PDP) advises there
have been changes to its Board of Directors. Mr. Angelo Botter has
resigned as a director of the Company to pursue other matters. The
Corporation's board of directors would like to thank Mr. Botter for
his invaluable contribution to the success of Pediapharm since it
was founded and wish him well in his future endeavors.
The Corporation is pleased to announce that Michael P. Mueller
has agreed to join the Board of Directors. Mr. Mueller is currently
the Chairman of Annidis Corporation and a director of several
companies including PSP Investments, the Canadian Tire Bank, Magor
Communications Corp. and Emily's House. From 2003 to 2005, he was
the President and CEO of MDS Capital Corporation. Mr. Mueller
previously held a series of senior executive positions at TD Bank,
including Vice Chairman and Global Head of Investment and Corporate
Banking. He is a former member of the Board of Directors of the
Scarborough Hospital (past Chair), the Scarborough Hospital
Foundation, AIM Therapeutics Inc., Biovest Corp. 1, Budco, TM
BioScience, MDS Capital Corporation and Canadian Medical
Discoveries Funds I and II. Mr. Mueller holds a Bachelor of Science
from the University of Western Ontario and an MBA from York
University.
"We are very much looking forward to Mr. Mueller's contributions
as he brings tremendous experience not only in the health care
sector but also in the small cap investment space. It was also
important for us to bring expertise and Board presence across
Canada and Mike's appointment fits perfectly with this objective"
said Sylvain Chretien, President and CEO of Pediapharm.
"Pediapharm will greatly benefit from Mr. Mueller's extensive
background and experience. Mike definitely brings a complementary
skill set to the existing Board and management team and we are
looking forward to his contributions," commented Mr. Pierre
Lapalme, Chairman of Pediapharm.
About Pedipharm Inc.
Pediapharm is the only Canadian specialty pharmaceutical company
dedicated to serving the needs of the pediatric community. Its
mission is to bring to the Canadian market the latest innovative
pediatric products with the objective to improve the health and the
well-being of children in Canada. Since its debut in 2008,
Pediapharm has entered into numerous commercial agreements with
partners from Canada and other countries around the world. The
company's innovative product portfolio includes NYDA®; a
breakthrough treatment for head lice; EpiCeram® a non-steroid
emulsion for eczema; KoolEffect™ which reduces the symptoms of
fever; and VapoLyptus™; a soothing vapour patch of Eucalyptus and
Camphor.
Neither the TSX Venture Exchange nor its Regulation Service
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Pediapharm Inc.Sylvain ChretienPresident and Chief Executive
Officer+1-514-762-2626 ext.
201sylvain.chretien@pedia-pharm.comRoland BoivinChief Financial
Officer+1-514-762-2626 ext.
202roland.boivin@pedia-pharm.comRelations Publiques Paradox Public
Relations Inc.Carl
Desjardins+1-514-341-0408carldesjardins@paradox-pr.ca
Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Pediapharm (TSX Venture Börse): 0 Nachrichtenartikel
Weitere Pediapharm News-Artikel